S 
Shanghai Shenqi Pharmaceutical Investment Management Co 600613.SS · CNY
Health Care · Shanghai · 🇨🇳 China
6.51
+1.72%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥1.95bn
FY2016FY2025
Net income
CN¥38.2m
FY2016FY2025
Free cash flow
CN¥91.3m
FY2016FY2025
Shareholders' equity
CN¥2.32bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥1.95bn | CN¥2.05bn | CN¥2.34bn | CN¥2.39bn | CN¥2.30bn | CN¥1.82bn | CN¥1.93bn | CN¥1.85bn | CN¥1.74bn | CN¥1.60bn |
| Gross profit | CN¥880.7m | CN¥951.7m | CN¥1.15bn | CN¥1.26bn | CN¥1.38bn | CN¥1.07bn | CN¥1.21bn | CN¥1.13bn | CN¥1.04bn | CN¥1.06bn |
| Research and development | CN¥30.2m | CN¥32.9m | CN¥32.3m | CN¥46.0m | CN¥50.9m | CN¥42.8m | CN¥20.0m | CN¥22.8m | CN¥23.9m | CN¥14.7m |
| Operating income | CN¥74.0m | CN¥91.7m | CN¥93.8m | CN¥65.9m | CN¥108.3m | −CN¥333.7m | CN¥108.4m | CN¥129.0m | CN¥159.3m | CN¥198.5m |
| Net income | CN¥38.2m | CN¥71.4m | CN¥57.0m | CN¥48.5m | CN¥69.6m | −CN¥341.2m | CN¥84.0m | CN¥106.1m | CN¥129.6m | CN¥182.1m |
| Diluted earnings per share | 0.07 | 0.12 | 0.13 | 0.10 | 0.13 | -0.68 | 0.19 | 0.21 | 0.24 | 0.36 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥3.15bn | CN¥3.12bn | CN¥3.28bn | CN¥3.38bn | CN¥3.15bn | CN¥3.10bn | CN¥3.56bn | CN¥3.13bn | CN¥3.10bn | CN¥3.00bn |
| Cash and short-term investments | — | CN¥800.3m | CN¥736.2m | CN¥656.5m | CN¥493.8m | CN¥481.5m | CN¥596.1m | CN¥205.8m | CN¥284.3m | CN¥309.2m |
| Total liabilities | CN¥747.6m | CN¥689.0m | CN¥888.8m | CN¥1.01bn | CN¥756.5m | CN¥770.3m | CN¥894.6m | CN¥527.7m | CN¥565.3m | CN¥567.6m |
| Debt | CN¥88.6m | CN¥167.1m | CN¥253.1m | CN¥285.6m | CN¥312.3m | CN¥343.6m | CN¥402.9m | CN¥27.1m | CN¥128.0m | CN¥80.0m |
| Shareholders' equity | CN¥2.32bn | CN¥2.36bn | CN¥2.34bn | CN¥2.33bn | CN¥2.34bn | CN¥2.28bn | CN¥2.62bn | CN¥2.54bn | CN¥2.46bn | CN¥2.36bn |
| Shares outstanding | 583m | 578m | 424m | 494m | 552m | 500m | 450m | 504m | 549m | 508m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥124.5m | CN¥207.8m | CN¥215.6m | CN¥319.2m | CN¥184.3m | CN¥99.1m | CN¥128.3m | CN¥148.5m | CN¥67.0m | CN¥570,413 |
| Capital spending | −CN¥33.2m | −CN¥36.4m | −CN¥24.5m | −CN¥26.6m | −CN¥86.0m | −CN¥96.3m | −CN¥77.0m | −CN¥110.2m | −CN¥108.8m | −CN¥42.9m |
| Free cash flow | CN¥91.3m | CN¥171.4m | CN¥191.1m | CN¥292.6m | CN¥98.3m | CN¥2.8m | CN¥51.3m | CN¥38.3m | −CN¥41.9m | −CN¥42.3m |
| Dividends paid | −CN¥88.2m | −CN¥64.2m | −CN¥66.3m | −CN¥53.5m | −CN¥4.0m | −CN¥5.8m | −CN¥4.4m | −CN¥22.0m | −CN¥29.6m | −CN¥37.2m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥425.2m | CN¥422.9m | CN¥554.5m | CN¥437.0m | CN¥480.9m | CN¥479.9m | CN¥485.5m | CN¥452.9m |
| Gross profit | CN¥182.3m | CN¥190.9m | CN¥222.9m | CN¥215.7m | CN¥217.6m | CN¥224.5m | CN¥187.6m | CN¥239.2m |
| Operating income | CN¥36.0m | CN¥26.2m | CN¥25.3m | CN¥20.1m | CN¥25.3m | CN¥20.9m | CN¥17.3m | CN¥26.4m |
| Net income | CN¥9.1m | CN¥12.9m | −CN¥12.1m | CN¥17.5m | CN¥17.8m | CN¥15.0m | CN¥12.0m | CN¥21.5m |
| Diluted earnings per share | 0.02 | 0.02 | -0.02 | 0.03 | 0.03 | 0.03 | 0.02 | 0.04 |
| Cash from operations | — | — | — | CN¥109.0m | CN¥76.0m | −CN¥28.0m | — | CN¥58.0m |
| Capital spending | −CN¥2.0m | −CN¥3.0m | −CN¥8.0m | −CN¥6.0m | −CN¥5.0m | −CN¥12.0m | −CN¥19.0m | −CN¥10.0m |
| Free cash flow | — | — | — | CN¥103.0m | CN¥71.0m | −CN¥40.0m | — | CN¥48.0m |
| Total assets | CN¥2.90bn | CN¥3.04bn | CN¥3.15bn | CN¥3.09bn | CN¥3.00bn | CN¥3.12bn | CN¥3.12bn | CN¥3.21bn |
| Cash and short-term investments | — | — | — | CN¥821.7m | CN¥721.5m | CN¥796.3m | CN¥800.3m | CN¥874.1m |
| Debt | — | — | CN¥88.6m | CN¥74.5m | CN¥148.7m | CN¥161.6m | CN¥156.6m | CN¥189.8m |
| Shareholders' equity | CN¥2.30bn | CN¥2.33bn | CN¥2.32bn | CN¥2.33bn | CN¥2.31bn | CN¥2.37bn | CN¥2.36bn | CN¥2.35bn |
Financial ratios
Data as of 23 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 45.1% | 46.5% | 49.2% | 52.9% | 60.1% | 58.9% |
| Operating margin | 4.1% | 5.0% | 4.2% | 3.4% | 4.7% | -18.3% |
| Net margin | 2.0% | 3.5% | 2.4% | 2.0% | 3.0% | -18.8% |
| Return on equity | 1.6% | 3.0% | 2.4% | 2.1% | 3.0% | -15.0% |
| Return on assets | 1.2% | 2.3% | 1.7% | 1.4% | 2.2% | -11.0% |
| Free cash flow yield | 4.0% | 6.3% | 8.5% | 10.5% | 7.3% | 5.8% |
| Revenue growth | -4.7% | -12.5% | -2.0% | 3.7% | 26.6% | -5.6% |
| Earnings growth | -46.4% | 25.2% | 17.4% | -30.3% | -120.4% | -506.3% |
| Current ratio | 2.66x | 3.01x | 2.58x | 2.29x | 3.01x | 3.13x |
| Debt to equity | 0.04x | 0.07x | 0.10x | 0.10x | 0.10x | 0.13x |
| Equity ratio | 73.8% | 75.8% | 71.2% | 68.8% | 74.4% | 73.5% |
| Interest coverage | 8.04x | 7.11x | 6.19x | 4.39x | 11.59x | -50.53x |
| R&D as a share of sales | 1.5% | 1.6% | 1.4% | 1.9% | 2.2% | 2.4% |
| Buybacks as a share of market value | -0.9% | -36.3% | 14.2% | 10.4% | -10.4% | -11.1% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | -6.5% | 1.4% | 2.1% |
| Operating income | 4.0% | — | -11.6% |
| Net income | -7.6% | — | -15.9% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 45.8% | 48.7% | 52.2% | 57.1% |
| Operating margin | 4.1% | 3.7% | 0.8% | 4.4% |
| Net margin | 2.7% | 2.5% | -0.4% | 3.1% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 92.4 | 55.5 | 56.6 | 83.8 | 50.9 | -7.2 | 38.7 | 23.3 | 35.4 | 39.1 |
| Price to sales | 1.8 | 1.9 | 1.4 | 1.7 | 1.5 | 1.4 | 1.7 | 1.3 | 2.6 | 4.5 |
Dividends and splits
Per share, in the currency the company pays
Paid for 4 years. Last went ex-dividend on 17 Jun 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.07 | 0.15 | 0.10 | 0.10 | 0.10 | 0.03 | 0.03 | 0.065 |
- 6-for-5 split · 6 Jul 2015
- 1-to-1 reverse split · 28 Jul 2006
- 1.15-for-1 split · 21 Jul 1998
- 1.15-for-1 split · 14 Jul 1997
- 1.15-for-1 split · 8 Jul 1996
- 6-for-5 split · 13 Sept 1993
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.